On this episode of The Point, a podcast from The Texas Heart Institute, host Dr. Alexander Postalian joins guests Dr. Brett Doliner and Dr. Ramsey Kalil, to discuss key aspects of Hypertrophic Cardiomyopathy (HCM). They draw from their expertise and a recent publication in the Texas Heart Institute Journal: "Modern Perspectives on Hypertrophic Cardiomyopathy—No One Size Fits All." 

Join the conversation as we unpack key aspects of hypertrophic cardiomyopathy:

• Diagnosing HCM: How do we identify this condition, and why is it complicated?
• Athlete Screening: What are the tough choices and ethical questions when screening athletes?
• HCM Treatment: What are the available options, from simple to complex?
• Personalized Care: Why is tailoring treatment so vital for HCM patients?

Watch On Demand Videos on Texas Heart TV

Visit Our Website: texasheart.org

The Texas Heart Institute’s Drs Salim Virani and Matthew Segar look back at the history of SGLT2 inhibitors, which have roots in a fascinating FDA initiative focused on cardiovascular outcomes in diabetes medications. They explore the serendipitous beginnings of these groundbreaking medicines and their significant impact on cardiovascular health.

Watch this episode on Texas Heart TV  

Allan Zhang, Ramsey Kalil, Alexander Marzec, Stephanie A. Coulter, Salim Virani, Kershaw V. Patel, Matthew W. Segar; Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Tex Heart Inst J 1 January 2024; 51 (1): e238375. doi: https://doi.org/10.14503/THIJ-23-8375

Watch On Demand Videos on Texas Heart TV

Visit Our Website: texasheart.org